• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

效应-时间模型中药代动力学半衰期与药效动力学半衰期之间的关系。

Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.

作者信息

Keller F, Czock D, Zellner D, Giehl M

机构信息

Medical Department, University Hospital, Ulm, Germany.

出版信息

Int J Clin Pharmacol Ther. 1998 Mar;36(3):168-75.

PMID:9562234
Abstract

A pharmacodynamic parameter relating time-dependent changes of the effect with time-dependent changes of concentrations has yet to be developed. In pharmacokinetics, half-lives (T1/2kin) are used to describe the relation between concentration (C) and time (t). In pharmacodynamics, often the sigmoid Emax model and the Hill equation are used (E = Emax CH/(EC50H + CH)) to describe the relation between effect (E) and concentration (C). To describe the correlation between effect (E) and time (t), a pharmacodynamic half-life (T1/2dyn) could be estimated if the use of the term half-life is not restricted only to log-linear first order processes. To bisect the drug effect a variable time (t1-2 = t2-t1) will be required for this nonlinear process. The bisection of the effect (E2 = 1/2 E1) is associated with a decrease in concentrations (C2 = C1 exp(-0.693 t1-2/T1/2kin)). A mathematical relationship can be derived between pharmacodynamic half-life (T1/2dyn = t1-2) and pharmacokinetic half-life (T1/2dyn = T1/2kin (ln (1 + ln(a)/ln(2))/H ) with (a = (EC50H + C1H)/(EC50H + C2H)). For concentrations in the range of the EC50 value with the Hill coefficient (H = 1), the pharmacodynamic half-life will be 1.6-2.0 times the kinetic half-life (T1/2dyn < or = 2.0 T1/2kin). For high concentrations (C1 > EC50), the dynamic half-life will grow much longer than the kinetic half-life, consequently the effect of a drug will not increase but it will last longer. The pharmacodynamic half-life turns out to be a specific estimate for the effect time relation, being a concentration-dependent function of the kinetic half-life.

摘要

一个将效应随时间的变化与浓度随时间的变化联系起来的药效学参数尚未被开发出来。在药代动力学中,半衰期(T1/2kin)用于描述浓度(C)与时间(t)之间的关系。在药效学中,常使用S形Emax模型和希尔方程(E = Emax CH/(EC50H + CH))来描述效应(E)与浓度(C)之间的关系。为了描述效应(E)与时间(t)之间的相关性,如果半衰期这一术语不限于对数线性一级过程,那么可以估计出药效学半衰期(T1/2dyn)。对于这个非线性过程,需要一个可变时间(t1-2 = t2 - t1)来平分药物效应。效应的平分(E2 = 1/2 E1)与浓度的降低(C2 = C1 exp(-0.693 t1-2/T1/2kin))相关。可以推导出药效学半衰期(T1/2dyn = t1-2)与药代动力学半衰期(T1/2dyn = T1/2kin (ln (1 + ln(a)/ln(2))/H )之间的数学关系,其中(a = (EC50H + C1H)/(EC50H + C2H))。对于希尔系数(H = 1)且浓度在EC50值范围内,药效学半衰期将是动力学半衰期的1.6 - 2.0倍(T1/2dyn ≤ 2.0 T1/2kin)。对于高浓度(C1 > EC50),动态半衰期将比动力学半衰期长得多,因此药物的效应不会增加但会持续更长时间。药效学半衰期结果是效应 - 时间关系的一个特定估计值,是动力学半衰期的浓度依赖性函数。

相似文献

1
Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.效应-时间模型中药代动力学半衰期与药效动力学半衰期之间的关系。
Int J Clin Pharmacol Ther. 1998 Mar;36(3):168-75.
2
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.药代动力学/药效学(PK/PD)建模的基本概念。
Int J Clin Pharmacol Ther. 1997 Oct;35(10):401-13.
3
Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.丙泊酚用于重症患者长期镇静的群体药代动力学和药效学建模:丙泊酚6%与丙泊酚1%的比较
Clin Pharmacol Ther. 2002 Dec;72(6):670-84. doi: 10.1067/mcp.2002.129500.
4
Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.苯妥英对大鼠抗惊厥及脑电图作用的药代动力学-药效学建模
J Pharmacol Exp Ther. 1998 Feb;284(2):460-6.
5
Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana.Δ⁹-四氢大麻酚的浓度-效应关系及吸食大麻后精神效应的预测
Int J Clin Pharmacol Ther. 1997 Apr;35(4):155-9.
6
Pharmacokinetic-pharmacodynamic relationship.药代动力学-药效学关系
Ann Rech Vet. 1990;21 Suppl 1:29S-40S.
7
Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation.阿芬太尼对大鼠脑电图影响的药代动力学-药效学建模:快速功能适应性评估
Br J Pharmacol. 1998 Aug;124(7):1534-40. doi: 10.1038/sj.bjp.0701972.
8
The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model.二室开放身体模型中半衰期(t1/2)与平均驻留时间(MRT)之间的关系。
Biopharm Drug Dispos. 2004 May;25(4):157-62. doi: 10.1002/bdd.396.
9
Pharmacokinetic and pharmacodynamic modeling in vivo.体内药代动力学和药效学建模
Crit Rev Bioeng. 1981;5(4):273-322.
10
Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery.口腔手术后疼痛患者中鼻内给予与静脉给予芬太尼的药代动力学和药效学
Ann Pharmacother. 2008 Oct;42(10):1380-7. doi: 10.1345/aph.1L168. Epub 2008 Aug 26.

引用本文的文献

1
Skipping a pillar does not make for strong foundations: Pharmacokinetic-pharmacodynamic reasoning behind the shape of dose-response relationships in oncology.跳过支柱无法建立坚实的基础:肿瘤学中剂量反应关系形态背后的药代动力学-药效学推理。
CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1591-1601. doi: 10.1002/psp4.13020. Epub 2023 Sep 28.
2
Time of effect duration and administration interval for sitagliptin in patients with kidney failure.西他列汀在肾衰竭患者中的疗效持续时间和给药间隔时间。
Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):77-85. doi: 10.1007/s13318-013-0164-7. Epub 2013 Dec 19.
3
Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
对于快速清除药物的缓释制剂,功能半衰期是稳态药代动力学的一个有意义的描述指标:如每日一次服用丙戊酸缓释片所示。
Clin Drug Investig. 2006;26(12):681-90. doi: 10.2165/00044011-200626120-00002.